| Literature DB >> 31179651 |
Youngsub Eom1, Kyung Sun Na2, Kyong Jin Cho3, Ho Sik Hwang2, Sun Woong Kim4, Tae Young Chung5, Roo Min Jun6, Jong Suk Song7, Hyun Seung Kim2.
Abstract
PURPOSE: We sought to evaluate the distribution and characteristics of meibomian gland dysfunction (MGD) and the treatment patterns for symptomatic MGD patients in South Korea.Entities:
Keywords: Classification; Diagnosis; Meibomian gland dysfunction; Meibomian glands; Therapeutics
Mesh:
Year: 2019 PMID: 31179651 PMCID: PMC6557798 DOI: 10.3341/kjo.2018.0104
Source DB: PubMed Journal: Korean J Ophthalmol ISSN: 1011-8942
Subtypes of MGD considered in this study
MGD = meibomian gland dysfunction.
*Clinically apparent inflammation and other signs of MGD pathology, such as pouting or capping of the meibomian gland orifices, erythema, an irregular and thickened eyelid margin, telangiectasia, and dimpling or notching of the posterior eyelid margin; †The proportion of expressible glands of the central eight glands in the eyelid as determined by mild cotton swab pressure.
Clinical characteristics of patients and their eyes (n = 196)
Values are presented as mean ± standard deviation (range) or number (%).
OSDI = Ocular Surface Disease Index; TBUT = tear film break-up time.
Comparison between upper and lower eyelids
Values are presented number (%) or as mean ± standard deviation.
*Chi-squared test; †Student's t-test.
Comparison of patient characteristics according to upper eyelid subtype (n = 196)
Values are presented as mean ± standard deviation or number (%).
OSDI = Ocular Surface Disease Index; TBUT = tear film break-up time.
*One-way analysis of variance; †Chi-squared test; ‡Fisher's exact test.
Comparison of patient characteristics according to lower eyelid subtype (n = 196)
Values are presented as mean ± standard deviation or number (%).
OSDI = Ocular Surface Disease Index; TBUT = tear film break-up time.
*One-way analysis of variance; †Chi-squared test; ‡Fisher's exact test.
Fig. 1Absolute frequency of treatment modalities for patients with meibomian gland dysfunction. HA = hyaluronic acid eye drops; CMC = carboxymethylcellulose eye drops.
Fig. 2Absolute frequency of treatment modalities for patients with meibomian gland dysfunction according to the subtype of the upper eyelid. HA = hyaluronic acid eye drops; CMC = carboxymethylcellulose eye drops. *p-value of less than 0.05.
Fig. 3Absolute frequency of treatment modalities for patients with meibomian gland dysfunction according to the subtype of the lower eyelid. HA = hyaluronic acid eye drops; CMC = carboxymethylcellulose eye drops. *p-value of less than 0.05.